Updates to the Evidence to Recommendation Framework: Pfizer-BioNTech and Moderna COVID-19 vaccine booster doses
A third Pfizer BioNTech covid-19 vaccine dose—known as a booster dose—provides “significant increased protection” against symptomatic disease in those aged 50 and over, irrespective of which vaccine they initially received.1 A study by the UK Health Security Agency (UKHSA) found that at least 20 weeks after being fully vaccinated with […]